Retatrutide: Best Telehealth Providers for Weight Loss Management (2026)
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Reviewed by Dr. James Okafor, PharmDPharmDRetatrutide at a Glance
Category
Weight Loss Management
Administration
Subcutaneous injection (weekly)
Telehealth Providers
3 compared
Price Range
$450 – $550/mo
Typical Dose
Investigational dosing in Phase 3
Frequency
Once weekly
Protocol Duration
Ongoing
Prescription
Required
Research highlight: Phase 3 TRIUMPH trials demonstrated 22-24% average weight loss at 48 weeks with retatrutide's first-in-class triple GLP-1/GIP/glucagon receptor agonism, with some patients achieving 30%+ body weight reduction.
What is Retatrutide Used For?
Also known as: LY3437943
- Weight loss
- Metabolic health
- Appetite suppression
- Blood sugar regulation
How Retatrutide Works
Retatrutide is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component — absent in tirzepatide — provides additional metabolic benefits: glucagon activates brown adipose tissue (increasing energy expenditure), enhances hepatic fat metabolism, and contributes to the appetite suppression effect. Phase 3 data show average weight loss of 22–24% at 48 weeks, with some patients losing 30%+.
RetatrutideDosing & Administration
| Typical Dose | Investigational dosing in Phase 3 |
| Frequency | Once weekly |
| Protocol Duration | Ongoing |
| Route | Subcutaneous injection (weekly) |
Dosing information is for educational purposes only. Your prescribing physician will determine the appropriate dose based on your medical history and treatment goals.
What to Expect from Retatrutide
Phase 3 TRIUMPH trials show weight loss beginning rapidly — roughly 5% in the first 4 weeks at higher doses. Average weight loss exceeds tirzepatide at 48 weeks (22–24% vs. 20–22%). The additional glucagon component appears to accelerate fat oxidation, producing faster early weight loss than GLP-1 alone or GLP-1/GIP combinations.
Who Should Consider Retatrutide?
- Severe obesity (BMI ≥35) seeking maximum weight loss
- Patients with suboptimal response to semaglutide or tirzepatide
- Those prioritizing maximum weight loss as the primary goal
- Patients comfortable with investigational-status medications under experienced providers
Retatrutide Side Effects
- Nausea (common during titration)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Potential: more pronounced GI side effects due to glucagon component at higher doses
This is not a complete list of side effects. Always consult your prescribing physician before starting Retatrutide.
3 Telehealth Providers Offering Retatrutide
Sorted by lowest price. All providers require a prescription from a licensed physician.
| Provider | Price | Dose | Rating | Consultation | Lab Testing |
|---|---|---|---|---|---|
| Defy Medical Tampa, FL | $450/monthly | Protocol varies | 4.1/5 | Video Telehealth | Included |
| Evolve Telemed San Diego, CA | $480/monthly | Protocol varies | 4.0/5 | Video Telehealth | Included |
| TruLife Health Scottsdale, AZ | $550/monthly | Protocol varies | 4.1/5 | Video Telehealth | Included |
How to Choose the Best Telehealth Provider for Weight Loss Management
Not all online weight-loss programs are equal. These are the criteria we evaluate when ranking telehealth providers for weight loss medications.
Licensed Medical Supervision
The best providers require a licensed physician or NP to review your health history and approve your prescription — not just an intake algorithm. Asynchronous intake is fine; skipping real medical review is not.
Transparent Per-Dose Pricing
Weight loss programs range from $99 to $500+/month for semaglutide. Look for providers that clearly state the dose included and cost per mg so you can compare programs on equal terms.
Compounding Pharmacy Quality
Compounded medications must come from an FDA-registered 503A or 503B pharmacy. Ask which pharmacy your provider uses and verify its accreditation — sterility and potency standards vary significantly.
Proper Dose Titration
GLP-1 medications should start at a low dose and escalate gradually over weeks. Providers who skip titration to speed results are prioritizing revenue over your safety.
Lab Monitoring
Baseline labs (metabolic panel, HbA1c, lipids) and periodic follow-up are standard of care for GLP-1 therapy. Providers who require or include labs are practicing at a higher standard.
Long-Term Support
Weight management is a long-term commitment. Look for providers with clear refill processes, messaging access to your care team, and supply chain stability beyond the promotional first month.
Frequently Asked Questions About Retatrutide
Is retatrutide FDA-approved?
As of 2025, retatrutide (LY3437943, Eli Lilly) is in Phase 3 clinical trials. It is not yet FDA-approved. It is available through investigational access and some compounding pharmacies, though availability may be limited and regulatory status is evolving.
How does retatrutide compare to tirzepatide?
Phase 3 data suggest retatrutide produces 3–5% more total weight loss than tirzepatide at 48 weeks, and with faster early weight loss due to the glucagon component. However, it may have slightly more GI side effects. Neither drug has been directly compared head-to-head in a Phase 3 trial.
Is the glucagon component in retatrutide safe?
Glucagon activates hepatic glucose production, which sounds counterintuitive for a diabetes or metabolic drug. However, the GLP-1 component simultaneously suppresses glucagon's blood-glucose-raising effect, so the net glycemic impact is still favorable. The glucagon component primarily contributes through increased energy expenditure and lipolysis.
Who is retatrutide best suited for?
Retatrutide targets patients with severe obesity (BMI ≥35) where maximum weight loss is the primary goal, or patients who have had suboptimal response to semaglutide or tirzepatide. Given its investigational status as of 2025, it is typically recommended only by providers experienced with off-label peptide prescribing.
Related Guides
- Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?
- GLP-1 Weight Loss Plateau: Why It Happens and What to Do About It
- GLP-1 Friendly Diet: What to Eat on Semaglutide, Tirzepatide & Other GLP-1s
- How to Start GLP-1 Treatment: Complete 7-Step Process Guide
- How to Calculate True GLP-1 Costs: Complete Methodology Guide 2026
Retatrutide Alternatives for Weight Loss Management
Compare other weight loss management peptides available through telehealth.
AOD-9604
A modified fragment (amino acids 176-191) of human growth hormone designed to stimulate fat metabolism without the growth-promoting effects of full HGH. Studied as a targeted fat-loss peptide.
Liraglutide
A GLP-1 receptor agonist administered daily for chronic weight management. FDA-approved as Saxenda for obesity and as Victoza for type 2 diabetes. One of the first GLP-1 medications widely used for weight loss before semaglutide.
Semaglutide
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. Reduces appetite and slows gastric emptying.
Tirzepatide
A dual GIP/GLP-1 receptor agonist for weight management and type 2 diabetes. Clinical trials show significant weight reduction, often exceeding semaglutide results.